ClinicalTrials.gg
Not yet recruitingNCT07709442SHINEUpdated Jul 16, 2026

Songling Xuemaikang in Hypertension and Insomnia Evaluation(SHINE)

An interventional study of Songling Xuemaikang Capsule and Songling Xuemaikang Capsule Simulant in Hypertension, sponsored by Jing Liu. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Jing Liu · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 410 studies in Hypertension with a site in China — 124 open to participants now, 148 under way, 12 of them phase 3. Hypertension · China.

Planned enrollment
149th of 308
260 · median 253
Started
2026
with 37 others
No phase
146 of 410
56 open now
Primary completion
2027-06
later than 98 of 147 live
Registered
387th of 410
by date

Among the 410 studies in Hypertension with a site in China, this one is the 149th largest by planned enrollment of the 308 interventional ones that give a count, is one of 38 that started in 2026, is one of 146 with no phase, reaches primary completion later than 98 of the 147 other live ones, and was the 387th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

124 of the 410 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:

119 more — sign in →

All 124 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 410 studies in Hypertension with a site in China, or all of them as a file.
02

Study summary

To evaluate the effect of Songling Xuemaikang Capsules on reducing 24-hour mean blood pressure in patients with hypertension accompanied by insomnia.

Read the detailed description

Disease Background: Hypertension is one of the major chronic non-communicable diseases in China, with an extremely severe epidemic situation, imposing a heavy burden on public health and the national medical system. According to the latest data, the weighted prevalence of hypertension among adults aged ≥18 years in China was 27.5% in 2018. A survey from 2012 to 2015 showed that the awareness, treatment, and control rates of hypertension among people aged over 18 years were 51.6%, 45.8%, and 16.8%, respectively. Healthy sleep includes sufficient sleep duration and good sleep quality. Healthy sleep is associated with a lower risk of hypertension, and with a lower incidence of coronary heart disease and stroke in hypertensive patients. Short sleep duration increases the risk of hypertension, and insomnia is associated with cardiovascular mortality and all-cause mortality. A meta-analysis conducted in 2024 included 32 sleep studies in China involving more than 370,000 participants, assessed by the Pittsburgh Sleep Quality Index (PSQI) with a cutoff score of 4-7 (68.8% of studies used a cutoff of 7 for sleep abnormality). The prevalence of poor sleep quality was found to be 19.0% (95% CI: 15.8%-22.8%). The proportion of sleep problems in the hypertensive population is higher than that in the general population. A meta-analysis published in 2020 included 24 studies involving 13,920 participants, revealing that the prevalence of sleep difficulty in hypertensive individuals was as high as 52.5% (95% CI: 46.1%-58.9%), compared with 32.5% (95% CI: 19.0%-49.7%) in healthy controls. The odds ratio (OR) of sleep difficulty in hypertensive patients was 2.66 (95% CI: 1.80-3.93).

There is a complex pathophysiological link between hypertension accompanied by insomnia, rather than coincidental overlap. Numerous studies have confirmed that insomnia is an independent risk factor for the development and progression of hypertension. Chronic insomnia can elevate blood pressure and heart rate and increase the risk of hypertension through mechanisms such as activating the sympathetic nervous system, disrupting hypothalamic-pituitary-adrenal (HPA) axis function, and promoting inflammatory responses. A meta-analysis showed that the relative risk (RR) of incident hypertension in individuals with insomnia was approximately 1.21. Conversely, hypertension itself and its therapeutic drugs may also cause or worsen insomnia. Hypertensive patients often experience impaired sleep quality due to nocturnal blood pressure fluctuations, excessive sympathetic activation, anxiety, or side effects of certain antihypertensive agents .

Therefore, the Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 Revised Edition) provides specific and practical recommendations for the management of sleep duration and quality, including screening for sleep disorders and blood pressure in targeted populations, and proposes specific measures such as cognitive behavioral therapy for insomnia, hypnotic medications, and reducing diuretic use at night. However, in clinical practice, concerns regarding long-term adherence to cognitive behavioral therapy for insomnia and the safety of long-term use of sedative-hypnotic drugs still compromise the synergistic management of hypertension accompanied by insomnia. Thus, the selection of a medication that can lower blood pressure and improve insomnia simultaneously is of great clinical value.

Drug Background: Songling Xuemaikang Capsule is an exclusive product of Chengdu Kanghong Pharmaceutical Co., Ltd., approved for marketing on February 12, 1996. Its formula consists of Pini Massonianae Folium (fresh pine needle), Puerariae Lobatae Radix (kudzu root), and Concha Margaritifera Usta (nacre powder). Its functions and indications are: calming the liver and suppressing yang, tranquilizing the heart and calming the nerves. It is used for headache, dizziness, irritability, palpitations, and insomnia caused by hyperactivity of liver yang; it is also indicated for hypertension and primary hyperlipidemia with the above symptoms.

The sovereign drug of Songling Xuemaikang Capsule is Pinus massoniana Lamb. (Masson pine), a plant of the Pinus genus in the Pinaceae family. It is widely distributed in the humid eastern subtropical regions of China and extends to the northern tropics. In the lower Yangtze River basin, it occurs below 700 m above sea level; in the middle reaches, below 1,100-1,200 m; and in western China, below 1,500 m. The needle of Pinus massoniana, also known as pine hair, is slender and needle-shaped, hence called "pine needle". The needles are in bundles of two, lanceolate, 12-20 cm long, soft and flexible, with resin canals marginal; young leaves are green, and fallen leaves are brown. When dried, a long and narrow groove appears in the center, showing the leaf characteristics. The surface is smooth, dull green, light and crisp, with a slight odor, astringent and bitter taste, and warm nature. Compendium of Materia Medica records: "Long-term administration of pine needles cures all diseases, calms the five zang-organs, promotes hair growth, resists cold and heat, endures wind and rain, lightens the body and replenishes qi, preserves the interior and prolongs life without grain." Pine needle enters the heart and liver meridians, with effects of dispelling wind and drying dampness, killing parasites and relieving itching, activating blood circulation and calming the nerves. It is commonly used for influenza, rheumatic arthralgia, traumatic swelling and pain, hypertension, hyperlipidemia, neurasthenia, eczema, etc. Modern pharmacological studies have shown that proanthocyanidins and shikimic acid in pine needle exert antihypertensive, lipid-lowering, antioxidant, antipyretic, analgesic, anti-inflammatory, and sedative effects.

Kudzu root is the dried root of Pueraria lobata (Willd.) Ohwi (Fabaceae), originating mainly from the Himalayan region of China and currently distributed in most parts of China, especially in hot southern areas. It was first recorded in Shennong's Classic of Materia Medica: "Kudzu root mainly treats thirst, high fever, vomiting, various impediments, raises yin qi, and relieves various toxins." The Pharmacopoeia of the People's Republic of China (2020 Edition) states that kudzu root is sweet, pungent, and cool in nature, acting on the spleen, stomach, and lung meridians. It has the effects of relieving muscles and reducing fever, promoting fluid production and quenching thirst, promoting eruption, elevating yang and stopping diarrhea, unblocking collaterals, and relieving alcoholism. Clinically, it is used for exterior fever with headache, stiff neck and back, incomplete measles, heat dysentery, diarrhea, dizziness and headache, apoplectic hemiplegia, chest stuffiness and heart pain, and alcohol-induced injury. Modern pharmacological studies have found that the active ingredients of kudzu root include isoflavonoids (daidzin, daidzein, puerarin, etc.), kudzuosides, coumarins, triterpenoids, alkaloids, and other compounds. Its modern pharmacological effects include antipyretic, lipid-lowering, hypoglycemic, antihypertensive, and antiarrhythmic actions. Puerarin in kudzu root can directly dilate blood vessels, reduce peripheral resistance, and exert a significant antihypertensive effect, effectively relieving the "neck tightness" symptom in hypertensive patients. It also improves microcirculation, resists arrhythmia and platelet aggregation, and lowers blood glucose and lipids, with anti-hypoxia and antioxidant effects.

Concha Margaritifera is the shell of Hyriopsis cumingii (Lea), Cristaria plicata (Leach) (Unionidae), or Pteria martensii (Dunker) (Pteriidae). Hyriopsis cumingii is mainly produced in Hebei, Jiangsu, Anhui, Zhejiang, etc.; Cristaria plicata is distributed in most parts of China; Pteria martensii is mainly produced in Hepu, Guangxi. Concha Margaritifera was first recorded in Supplement to Materia Medica of the Tang Dynasty: "Ground rotten shell powder taken orally treats regurgitation and phlegm retention in the chest and heart", indicating its effects of drying dampness and resolving phlegm, regulating qi and harmonizing the stomach. The Pharmacopoeia of the People's Republic of China (2020 Edition) records that Concha Margaritifera is cold and salty in nature, acting on the liver and heart meridians, with effects of calming the liver and suppressing yang, tranquilizing and calming convulsions, and improving eyesight and removing nebula. It is used for headache, dizziness, palpitations, insomnia, red eyes with nebula, and blurred vision. Zhang Bingcheng's Notes to Materia Medica states: "Tranquilizing the heart and calming palpitations, it treats mania and epilepsy due to phlegm confusion, enters the liver and improves eyesight", demonstrating its tranquilizing effect. Nacre powder is a fine powder prepared from the nacre layer of Concha Margaritifera after removing the middle and outer layers. Modern pharmacological studies have shown that Concha Margaritifera is rich in trace elements such as calcium, iron, sodium, and potassium, which inhibit the excitation of nerves and skeletal muscles, mainly affecting the rapid eye movement (REM) sleep stage, and may also indirectly influence sleep by regulating other physiological functions and metabolic balance. Jiang Shanshan et al. established an insomnia rat model by electrical stimulation and evaluated it with polysomnography. The results showed that, compared with synthetic sedative-hypnotics and heart-nourishing and nerve-calming herbs, heavy tranquilizing herbs represented by magnetite and cinnabar prolonged total sleep time in insomnia rats, mainly extending slow-wave sleep I, slow-wave sleep II, and REM sleep stages, with more significant effects. Liu Tong et al. established a mouse insomnia model with para-chlorophenylalanine (PCPA), and evaluated the sedative-hypnotic effect by observing spontaneous activity, measuring adrenocorticotropic hormone (ACTH) in serum by ELISA, and calculating brain weight and brain coefficient. Experiments confirmed that Concha Margaritifera exerted sedative and hypnotic effects in mice, and its oligopeptide components may be one of the material bases for efficacy, acting by regulating ACTH. Liu Dong et al.found that the active fractions of Concha Margaritifera increased the concentration of 5-hydroxytryptamine (5-HT), which may be related to the brain 5-HT synthetase inhibitor PCPA, ultimately achieving sedative and hypnotic effects.

In summary, the combination of fresh pine needle and kudzu root not only dissolves turbidity and lowers lipids to purify blood and improve blood viscosity, but also activates blood circulation and removes blood stasis to restore vascular elasticity and ameliorate vascular aging, thereby regulating blood pressure by improving hemorheology and peripheral vascular resistance. Combined with nacre powder, it synergistically calms the liver and suppresses yang, tranquilizes the heart and calms the nerves, and improves symptoms such as headache, dizziness, irritability, palpitations, and insomnia.

Study Objectives: On the basis of healthy lifestyle management for hypertension and using a matching placebo of Songling Xuemaikang Capsule as the control, this study will evaluate the efficacy of Songling Xuemaikang Capsule in patients with hypertension accompanied by insomnia by assessing 24-hour ambulatory blood pressure, polysomnography, sleep and anxiety scales, and other measurements. Specifically, it will characterize its effects on 24-hour mean blood pressure, daytime and nighttime blood pressure reduction, blood pressure stability, sleep architecture, and symptom improvement, in order to evaluate the therapeutic efficacy of Songling Xuemaikang Capsule in this population.

03

Conditions studied

  • Hypertension

Keywords

  • Insomnia
  • Hypertension
  • Songling Xuemaikang Capsules
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-79 years (inclusive), male or female;
  2. Meet diagnostic criteria for essential hypertension, and satisfy one of the following conditions:

    Grade 1 hypertension with no antihypertensive drugs in the past 2 weeks; Receiving stable treatment with one standard-dose chemical antihypertensive agent for at least 4 weeks, with blood pressure(BP)140-159/90-99 mmHg, and is willing to maintain the treatment regimen without adjustment;

  3. Insomnia Serverity Index (ISI) score ≥ 8, symptoms occur for at least 3 nights per week and have persisted for no less than 3 months;
  4. No sedative-hypnotic drugs have been taken within the preceding one month;
  5. Is able to complete scale assessments independently;
  6. Is willing and able to comply with all examinations and observations specified in the protocol; Has provided written .

Exclusion criteria

Exclusion Criteria:

  1. Severe hypertension (mean SBP ≥ 180 mmHg and/or mean DBP ≥ 110 mmHg); malignant hypertension, hypertensive emergency, hypertensive crisis, hypertensive encephalopathy, etc.
  2. Suspected secondary hypertension (renal parenchymal hypertension, renovascular hypertension, obstructive sleep apnea, primary aldosteronism or other endocrine hypertension, drug-induced hypertension, monogenic hypertension, etc.);
  3. laboratory abnormalities at screening: > 1.5 × , AST > 1.5 × ULN, or Serum creatinine ≥ 2.0 mg/dL;
  4. Chronic gastrointestinal disorders accompanied by frequent abdominal pain or diarrhea, or history of gastrointestinal surgery that may impair drug absorption;
  5. A history of allergic diathesis or to any component of the product;
  6. Pregnant females,or those with a positive pregnancy test at screening, women planning pregnancy during the study, lactating women, or fertile women without adequate protection;
  7. Clinically severe and unstable hepatic, renal, hematologic disease, malignant tumor, or unilateral/bilateral renal artery stenosis;
  8. Documented psychiatric disorder, or GAD-7 score ≥ 10 or PHQ-9 score ≥ 10;
  9. Insomnia due to hyperthyroidism, restless legs syndrome, narcolepsy, sleep-related movement disorders, etc.;
  10. Insomnia due to neurodegenerative diseases (Parkinson's disease, Alzheimer's disease, epilepsy, etc.);
  11. Acute stroke;
  12. Confirmed diagnosis of OSA or STOP-BANG score ≥ 5;
  13. Night shift or rotating shift workers;
  14. Suspected or confirmed alcohol or drug abuse/dependence;
  15. Participation in another clinical trial within 3 months prior to screening; Any other condition deemed by the investigator to render the subject unsuitable for the trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Songling Xuemaikang Capsule

    Drug: Songling Xuemaikang Capsule

  • Placebo comparator
    Songling Xuemaikang Capsule Simulant

    Drug: Songling Xuemaikang Capsule Simulant

Interventions

  • DrugSongling xuemaikangStudies of Songling xuemaikangSongling xuemaikang pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    3 capsules each time, 3 times a day, for 12 consecutive weeks.

  • DrugSongling Xuemaikang Capsule Simulant

    Songling Xuemaikang Capsule Simulant, 3 capsules each time, 3 times a day, for 12 consecutive weeks.

06

What researchers measure

Primary outcomes

  1. Change from baseline in 24-hour mean systolic blood pressure at Week 12.

    Time frame: From baseline to Week 12.

Secondary outcomes

  1. Blood pressure-related parameters

    Changes from baseline in 24-hour mean diastolic blood pressure (DBP), daytime mean SBP/DBP, nighttime mean SBP/DBP, 24-hour pulse pressure, and 24-hour blood pressure load at Week 12. Changes from baseline in office sitting SBP/DBP at Weeks 4, 8, and 12. Changes from baseline in home blood pressure (optional) at Weeks 4, 8, and 12. Changes from baseline in blood pressure variability. Office sitting blood pressure control rate at Weeks 4, 8, and 12. Changes from baseline in ambulatory arterial stiffness index (AASI) at Week 12. Changes from baseline in morning surge index (MSI) at Week 12. 24-h blood pressure control rate at Week 12.

    Time frame: From baseline to Weeks 4, 8, and 12.

  2. Other detection parameters

    Changes from baseline in urinary albumin-to-creatinine ratio (UACR) after 12 weeks of treatment.

    Time frame: From baseline to Week 12.

  3. Other detection parameters

    TC

    Time frame: From baseline to Week 12

  4. Scale assessments

    The Pittsburgh Sleep Quality Index (PSQI) has a total score ranging from 0 to 21, with higher scores indicating poorer sleep quality.

    Time frame: From baseline to Weeks 4, 8, and 12.

  5. Scale assessments

    The Epworth Sleepiness Scale (ESS) has a total score ranging from 0 to 24, with higher scores indicating a greater degree of daytime sleepiness.

    Time frame: From baseline to Weeks 4, 8, and 12.

  6. Scale assessments

    The Generalized Anxiety Disorder 7-item scale (GAD-7) has a total score ranging from 0 to 21, with higher scores indicating more severe anxiety.

    Time frame: From baseline to Weeks 4, 8, and 12.]

  7. Scale assessments

    The Patient Health Questionnaire 9-item scale (PHQ-9) has a total score ranging from 0 to 27, with higher scores indicating more severe depression.

    Time frame: From baseline to Weeks 4, 8, and 12.]

  8. Scale assessments

    The 36-Item Short Form Health Survey (SF-36) has a total score ranging from 0 to 100, with higher scores indicating better quality of life and health status.

    Time frame: From baseline to Weeks 4, 8, and 12.

  9. Scale assessments

    The Sleep Diary measured on a 0-to-5 scale, where 0 indicates the worst and 5 indicates the best.

    Time frame: From baseline to Weeks 4, 8, and 12.

  10. Scale assessments

    The hypertension symptom scores has a total score ranging from 0 to 40, with higher scores indicating more frequent or severe hypertension-related symptoms.

    Time frame: From baseline to Weeks 4, 8, and 12.

  11. Polysomnography (PSG, optional)

    Sleep period time (SPT), measured in minutes.

    Time frame: From baseline to Week 12.

  12. Polysomnography (PSG, optional)

    Sleep latency, measured in minutes.

    Time frame: From baseline to Week 12.

  13. Polysomnography (PSG, optional)

    Total sleep time (TST), measured in minutes.

    Time frame: From baseline to Week 12.

  14. Polysomnography (PSG, optional)

    Wake after sleep onset (WASO), measured in minutes.

    Time frame: From baseline to Week 12.

  15. Polysomnography (PSG, optional)

    Sleep efficiency, measured in percentage (%).

    Time frame: From baseline to Week 12.

  16. Polysomnography (PSG, optional)

    Percentage of each sleep stage, measured in percentage (%).

    Time frame: From baseline to Week 12.

  17. Polysomnography (PSG, optional)

    Sleep stage transition index, measured in events per hour (events/hour).

    Time frame: From baseline to Week 12.

  18. Polysomnography (PSG, optional)

    Arousal index, measured in events per hour (events/hour).

    Time frame: From baseline to Week 12.

  19. Polysomnography (PSG, optional)

    Apnea-hypopnea index (AHI), measured in events per hour (events/hour).

    Time frame: From baseline to Week 12.

  20. 0ther detection parameters

    Urinary albumin-to-creatinine ratio (UACR), measured in mg/g.

    Time frame: From baseline to Week 12.

  21. Blood lipids

    Total cholesterol (TC), measured in mmol/L.

    Time frame: From baseline to Week 12.

  22. Blood lipids

    Triglyceride (TG), measured in U/L.

    Time frame: From baseline to Week 12.

  23. Blood lipids

    High-density lipoprotein cholesterol (HDL-C), measured in mmol/L.

    Time frame: From baseline to Week 12.

  24. Blood lipids

    Low-density lipoprotein cholesterol (LDL-C), measured in mmol/L.

    Time frame: From baseline to Week 12.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 12 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2026
First posted
Jul 16, 2026
StartEst.
Jun 30, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Apr 30, 2028
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07709442
Lead sponsor
Jing Liu
Responsible party
Jing Liu (Director of the Department of Hypertension, Peking University People's Hospital) — Sponsor-investigator
First posted
Jul 16, 2026
Start date
Jun 30, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Jul 16, 2026

Study contacts

Jing Liu, MD
Contact
heartcenter@163.com
+86 10 88325457

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Songling xuemaikang

Start the discussion